<DOC>
	<DOCNO>NCT00436904</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , alemtuzumab rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Giving alemtuzumab together rituximab may kill cancer cell . PURPOSE : This phase II trial study side effect well give alemtuzumab together rituximab work treat patient high-risk , early-stage chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Alemtuzumab Rituximab Treating Patients With High-Risk , Early-Stage Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine rate complete overall response alemtuzumab rituximab patient high-risk , early-stage chronic lymphocytic leukemia . - Determine toxicity regimen patient . Secondary - Determine overall survival time progression patient treat regimen . - Determine time response duration response patient treat regimen . - Correlate prognostic marker 11q- , 17p- , unmutated VH gene , CD38+ clinical outcome . - Determine response regimen use expanded definition response include minimal residual disease detect sensitive flow cytometry patient complete clinical remission single rearrange IgVH gene detect polymerase chain reaction patient monoclonal population flow cytometry . - Correlate vitro response clinical outcome patient treat regimen . - Determine alemtuzumab rituximab synergistic vitro . - Determine mechanism action regimen vitro . - Determine effect regimen immune function . - Monitor T-lymphocyte , natural killer cell , monocyte number treatment patient . - Serially evaluate T-lymphocyte immunophenotype function patient treat regimen . - Monitor recovery humoral immunity serial serum protein electrophoresis , immunofixation electrophoresis , immunoglobulin quantification . OUTLINE : - Dose-escalation ( week 1 ) : Patients receive rituximab IV day 1 escalating dos alemtuzumab subcutaneously ( SC ) day 3-5 week 1 . - Treatment ( week 2-5 ) : Patients receive alemtuzumab SC day 1-3 ( high dose administer week 1 ) rituximab IV day 3 week 2-5 absence disease progression unacceptable toxicity . Patients undergo blood collection baseline periodically study treatment pharmacokinetic prognostic biomarker ( 11q- , 17p- , unmutated IgVH , CD38 expression flow cytometry fluorescent in-situ hybridization ) study . Immune function ( CDR3 T-cell receptor reverse transcriptase-polymerase chain reaction ) vitro vivo response also examine . After completion study therapy , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 33 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : * Diagnosis Bcell chronic lymphocytic leukemia ( CLL ) Earlystage , biologically highrisk disease define follow criterion : Rai stage 0II ( meet standard NCIsponsored Working Group criteria treatment ) Clinical phenotypic feature manifest peripheral blood , include follow : Minimum threshold peripheral blood lymphocyte count &gt; 5,000/mm³ Smalltomoderate peripheral blood lymphocyte ≤ 55 % prolymphocytes Monoclonality B lymphocytes immunophenotypic evaluation , demonstrate coexpression CD19 , CD5 , CD23 antigens , surface expression CD20 CD52 , Bcell monoclonal population define lightchain exclusion Poor prognosis demonstrate ≥ 1 follow highrisk parameter : Unmutated human immunoglobulin variable region heavy chain ( IgVH ) gene CD38 expression ( ≥ 30 % cell positive flow cytometry ) OR unmutated IgVH ZAP70 expression ( ≥ 20 % cell positive flow cytometry ) = 11q = 17p PATIENT CHARACTERISTICS : ECOG performance status 02 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Creatinine ≤ 1.5 time upper limit normal ( ULN ) Total bilirubin ≤ 3.0 time ULN OR direct bilirubin ≤ 1.5 time ULN AST ≤ 3.0 time ULN ( unless due hemolysis CLL ) Hemoglobin ≥ 9.0 g/dL No New York Heart Association class IIIIV heart disease No myocardial infarction within past month No uncontrolled infection No active HIV infection No evidence autoimmune hemolytic anemia , immune thrombocytopenia , pure red blood cell aplasia No active primary malignancy require treatment limit survival le 2 year PRIOR CONCURRENT THERAPY : No prior treatment CLL Prior corticosteroid allow No prior radiotherapy More 4 week since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>stage 0 chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
</DOC>